SignaBlok awarded NCI / NIH SBIR Phase I grant to test TREM-1 therapy for pancreatic cancer

SignaBlok > News

SignaBlok > News

SignaBlok awarded NCI / NIH SBIR Phase I grant to test TREM-1 therapy for pancreatic cancer

SignaBlok presented preclinical data showcasing company’s peptide therapeutic programs in cancer, inflammation and autoimmune diseases at the 2015 Therapeutics Stream at the Essential Protein Engineering Summit (PEGS) Annual Meeting

SignaBlok awarded NIAMS / NIH SBIR Phase I grant to test new therapy for rheumatoid arthritis

Blockade of TREM-1 prevents vitreoretinal neovascularization in mice with oxygen-induced retinopathy

Rojas MA, Shen ZT et al. Biochim Biophys Acta Mol Basis Dis. 2018

SignaBlok wins NHLBI / NIH SBIR Phase II grant to test SignaBlok’s ultra high sensitivity MRI contrast agents for atherosclerosis imaging in rodent and non-rodent animal models

SignaBlok presented proof-of-concept animal data on development of novel MRI contrast agent for diagnostic imaging of atherosclerosis at the 2014 Joint Annual Meeting ISMRM-ESMRMB

SignaBlok presented proof-of-concept animal data on development of a novel ligand-independent inhibitor of TREM-1 for treatment of sepsis and lung cancer at the 2014 AACR Annual Meeting

SignaBlok presented TREM-1 program in inflammation and cancer at the 2014 Inflammation, Infection and Cancer Keystone Symposium

Inhibition of TREM-2 markedly suppresses joint inflammation and damage in experimental arthritis

Sigalov AB. Int J Mol Sci. 2022

Rationally designed ligand-independent peptide inhibitors of TREM-1 ameliorate collagen-induced arthritis

Shen ZT and Sigalov AB. J Cell Mol Med. 2017